Insulin-like growth factors

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 169-178

  McCowen, Karen C ^a,d   Smith, Robert J ^b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970998236     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (102)

1. Froesch ER, Zapf J. Insulin-like growth factors and insulin: comparative aspects. Diabetologia 1985;28:485-493.
2. Scacchi M, Pincelli AI, Caumo A, et al. Spontaneous nocturnal growth hormone secretion in anorexia nervosa. . Clin Endocrinol Metab 1997;82: 3225-3229.
3. Oster MH, Fielder PJ, Levin N, et al. Adaptation of the growth hormone and insulin-like growth factor-I axis to chronic and severe calorie or protein malnutrition. . Clin Invest 1995;95:2258-2265.
4. Martinez V, Balbin M, Ordonez FA, et al. Hepatic expression of growth hormone receptor/binding protein and insulin-like growth factor I genes in uremic rats. Influence of nutritional deficit. Growth Horm IGF Res 1999;9:61-68.
5. Hintz RL, Suskind R, Amatayakul K, et al. Plasma somatomedin and growth hormone values in children with protein-calorie malnutrition. . Pediatr 1978;92:153-156.
6. Oster MH, Levin N, Fielder PJ, et al. Developmental differences in the IGF-I system response to severe and chronic calorie malnutrition. Am J Physiol 1996;270:E646-E653.
7. Ho KY, Veldhuis JD, Johnson ML, et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. . Clin Invest 1988;81:968-975.
8. Maes ML, Underwood E, Ketelslegers JM. Plasma somatomedin-C in fasted and refed rats: close relationship with changes in liver somatogenic but not lactogenic binding sites. . Endocrinol 1983;97:243-252.
9. Maiter D, Maes M, Underwood LE, et al. Early changes in serum concentrations of somatomedin-C induced by dietary protein deprivation in rats: contributions of growth hormone receptor and post-receptor defects. . Endocrinol 1988;118:113-120.
10. Bornfeldt KE, Arnqvist HJ, Enberg B, et al. Regulation of insulin-like growth factor-I and growth hormone receptor gene expression by diabetes and nutritional state in rat tissues. . Endocrinol 1989;122:651-656.
11. Straus DS, Takemoto CD. Effect of fasting on insulin-like growth factor-I (IGF-I) and growth hormone receptor mRNA levels and IGF-I gene transcription in rat liver. Mol Endocrinol 1990;4:91-100.
12. Donahue SP, Phillips LS. Response of IGF-1 to nutritional support in malnourished hospital patients: a possible indicator of short-term changes in nutritional status. Am J Clin Nutr 1989;50:962-969.
13. Clemmons DR, Underwood LE, Dickerson RN, et al. Use of plasma somatomedin-C/insulin-like growth factor I measurements to monitor the response to nutritional repletion in malnourished patients. Am J Clin Nutr 1985;41:191-198.
14. Isley WL, Underwood LE, Clemmons DR. Changes in plasma somatomedin-C in response to ingestion of diets with variable protein and energy content. JPEN J Parenter Enteral Nutr 1984;8:407-411.
15. Snyder DK, Clemmons DR, Underwood LE. Dietary carbohydrate content determines responsiveness to growth hormone in energy-restricted humans. . Clin Endocrinol Metab 1989;69:745-752.
16. Clemmons DR, Seek MM, Underwood LE. Supplemental essential amino acids augment the somatomedin-C/insulin-like growth factor I response to refeeding after fasting. Metabolism 1985;34:391-395.
17. Forbes GB, Brown MR, Welle SL, et al. Hormonal response to overfeeding. Am J Clin Nutr 1989;49:608-611.
18. Strasser-Vogel B, Blum WF, Past R, et al. Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment. . Clin Endocrinol Metab 1995;80:1207-1213.
19. Bornfeldt KE, Skottner A, Arnqvist HJ. In-vivo regulation of messenger RNA encoding insulin-like growth factor-I (IGF-I) and its receptor by diabetes, insulin and IGF-I in rat muscle. . Endocrinol 1992;135:203-211.
20. Cheetham TD, Taylor A, Holly JM, et al. The effects of recombinant human insulin-like growth factor-I (IGF-I) administration on the levels of IGF-I, IGFII and IGF-binding proteins in adolescents with insulin-dependent diabetes mellitus. . Endocrinol 1994;142:367-374.
21. Ekman B, Nystrom F, Arnqvist HJ. Circulating IGF-I concentrations are low and not correlated to glycaemic control in adults with type 1 diabetes. Eur J Endocrinol 2000;143:505-510.
22. Tollet P, Enberg B, Mode A. Growth hormone (GH) regulation of cytochrome P-450IIC12, insulin-like growth factor-I (IGF-I), and GH receptor messenger RNA expression in primary rat hepatocytes: a hormonal interplay with insulin, IGF-I, and thyroid hormone. Mol Endocrinol 1990;4:1934-1942.
23. Maiter D, Fliesen T, Underwood LE, et al. Dietary protein restriction decreases insulin-like growth factor I independent of insulin and liver growth hormone binding. Endocrinology 1989;124:2604-2611.
24. Bar RS, Boes M, Clemmons DR, et al. Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGFbinding proteins in the rat heart. Endocrinology 1990;127:497-499.
25. Takenaka A, Hirosawa M, Mori M, et al. Effect of protein nutrition on the mRNA content of insulin-like growth factor-binding protein-1 in liver and kidney of rats. Br J Nutr 1993;69:73-82.
26. Brisma K, Fernqvist-Forbes E, Wahren J, et al. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. . Clin Endocrinol Metab 1994; 79:872-878.
27. Radetti G, Paganini C, Antoniazzi F, et al. Growth hormone-binding proteins, IGF-I and IGF-binding proteins in children and adolescents with type 1 diabetes mellitus. Horm Res 1997;47:110-115.
28. Ogasawara M, Karey KP, Marquardt H, et al. Identification and purification of truncated insulin-like growth factor I from porcine uterus. Evidence for high biological potency. Biochemistry 1989;8:2710-2721.
29. Martin AA, Tomas FM, Owens PC, et al. IGF-I and its variant, des-(1-3)IGFI, enhance growth in rats with reduced renal mass. Am J Physiol 1991;261:F626-F633.
30. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. . Endocrinol 2002;175:19-31.
31. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. . Engl J Med 1987;317:137-140.
32. Livingston N, Pollare T, Lithell H, et al. Characterisation of insulin-like growth factor I receptor in skeletal muscles of normal and insulin resistant subjects. Diabetologia 1988;31:871-877.
33. Dohm GL, Elton CW, Raju MS, et al. IGF-I-stimulated glucose transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM. Diabetes 1990;39:1028-1032.
34. Sasaoka T, Ishiki M, Sawa T, et al. Comparison of the insulin and insulin-like growth factor 1 mitogenic intracellular signaling pathways. Endocrinology 1996;137:4427-4434.
35. Urso B, Cope DL, Kalloo-Hosein HE, et al. Differences in signaling properties of the cytoplasmic domains of the insulin receptor and insulin-like growth factor receptor in 3T3-L1 adipocytes. . Biol Chem 1999;274:30864-30873.
36. Kruger MS, Klein H, Siddle K, et al. Specificity of insulin and IGF-I receptors for IRS1. Exp Clin Endocrinol Diabetes 1996;104:38-39.
37. Urso BR, Brown A, O'Rahilly S, et al. The alpha-isoform of class II phosphoinositide 3-kinase is more effectively activated by insulin receptors than IGF receptors, and activation requires receptor NPEY motifs. FEBS Lett 1999;460:423-426.
38. Najjar SM, Blakesley VA, Li Calzi S, et al. Differential phosphorylation of pp120 by insulin and insulin-like growth factor-1 receptors: role for the C-terminal domain of the beta-subunit. Biochemistry 1997;36:6827-6834.
39. Beitner-Johnson D, LeRoith D. Insulin-like growth factor-I stimulates tyrosine phosphorylation of endogenous c-Crk. . Biol Chem 1995;270:5187-5190.
40. O'Neill TJ, Rose DW, Pillay TS, et al. Interaction of a GRB-IR splice variant (a human GRB10 homolog) with the insulin and insulin-like growth factor I receptors. Evidence for a role in mitogenic signaling. . Biol Chem 1996;271:22506-22513.
41. Hansen H, Svensson U, Zhu J, et al. Interaction between the Grb10 SH2 domain and the insulin receptor carboxyl terminus. . Biol Chem 1996;271:8882-8886.
42. Morrione A, Valentinis B, Li S, et al. Grb10: a new substrate of the insulin-like growth factor I receptor. Cancer Res 1969;56:3165-3167.
43. Laviola, L, Giorgino F, Chow JC, et al. The adapter protein Grb10 associates preferentially with the insulin receptor as compared with the IGF-I receptor in mouse fibroblasts. . Clin Invest 1997;99:830-837.
44. Dupont J, Khan J, Qu B, et al. Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology 2001;142:4969-4975.
45. Rothe KI, Accili D. Role of insulin receptors and IGF receptors in growth and development. Pediatr Nephrol 2000;14:558-561.
46. Accili D, Nakae J, Kim JJ, et al. Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. . Pediatr Endocrinol Metab 1999;12:475-485.
47. O'Rahilly S, Moller DE. Mutant insulin receptors in syndromes of insulin resistance. Clin Endocrinol (Oxf) 1992;36:121-132.
48. Nakae J, Kato M, Murashita M, et al. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. . Clin Endocrinol Metab 1998;83:542-549.
49. Desbois-Mouthon C, Danan C, Amselem S, et al. Severe resistance to insulin and insulin-like growth factor-I in cells from a patient with leprechaunism as a result of two mutations in the tyrosine kinase domain of the insulin receptor. Metabolism 1996;45:1493-1500.
50. Bailyes EM, Nave BT, Soos MA, et al. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 1997;327:209-215.
51. Federici M, Giaccari A, Hribal ML, et al. Evidence for glucose/hexosamine in vivo regulation of insulin/IGF-I hybrid receptor assembly. Diabetes 1999;48:2277-2285.
52. Spampinato D, Pandini G, Iuppa A, et al. Insulin/insulin-like growth factor I hybrid receptors overexpression is not an early defect in insulin-resistant subjects. . Clin Endocrinol Metab 2000;85:4219-4223.
53. Fernandez AM, Kim JK, Yakar S, et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 2001;15:1926-1934.
54. Bruning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559-569.
55. Baudry A, Lamothe B, Bucchini D, et al. IGF-1 receptor as an alternative receptor for metabolic signaling in insulin receptor-deficient muscle cells. FEBS Lett 2001;488:174-178.
56. Shefi-Friedman L, Wertheimer E, Shen S, et al. Increased IGFR activity and glucose transport in cultured skeletal muscle from insulin receptor null mice. Am J Physiol Endocrinol Metab 2001;281:E16-E24.
57. Abuzzahab MJ, Schneider A, Goddard A, et al. Human IGF-I receptor mutations resulting in pre-and post-natal growth retardation. . Engl J Med 2003;349:2211-2222.
58. Rasmussen SK, Lautier C, Hansen L, et al. Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to type 2 diabetes mellitus. . Clin Endocrinol Metab 2000;85:1606-1610.
59. Lemons JA, Ridenour R, Orsini EN. Congenital absence of the pancreas and intrauterine growth retardation. Pediatrics 1979;64:255-257.
60. Hattersley AT, Beards F, Ballantyne E, et al. Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat Genet 1998;19:268-270.
61. Jacob R, Barrett E, Plewe G, et al. Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. Comparison with insulin. . Clin Invest 1989;83:1717-1723.
62. Jacob RJ, Sherwin RS, Bowen L, et al. Metabolic effects of IGF-I and insulin in spontaneously diabetic BB/w rats. Am J Physiol 1991;260:E262-E268.
63. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005.
64. Ciaraldi TP, Carter L, Seipke G, et al. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. . Clin Endocrinol Metab 2001;86:5838-5847.
65. Hansen AP, Johansen K. Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia 1970;6:27-33.
66. Thirone AC, Carvalho CR, Brenelli SL, et al. Effect of chronic growth hormone treatment on insulin signal transduction in rat tissues. Mol Cell Endocrinol 1997;130:33-42.
67. Dunger DB, Cheetham TD, Crowne EC. Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus. Metabolism 1995;44:119-123.
68. Savage MO, Dunger DB. Recombinant IGF-I therapy in insulin-dependent diabetes mellitus. Diabetes Metab 1996;2:257-260.
69. Lanzetta P, Malara C. Cotherapy with recombinant human IGF-I and insulin improves glycemic control in type 1 diabetes. Diabetes Care 2000;23:436-437.
70. Thrailkill K, Quattrin T, Baker L, et al. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/ IGF-binding protein system. . Clin Endocrinol Metab 1997;82:1181-1187.
71. Cheetham TD, Jones J, Taylor AM, et al. The effects of recombinant insulinlike growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993;36:678-681.
72. Carroll PV, Umpleby M, Alexander EL, et al. Recombinant human insulinlike growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment. Clin Endocrinol (Oxf) 1998;49:739-746.
73. Carroll PV, Christ ER, Umpleby AM, et al. IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp. Diabetes 2000;49:789-796.
74. Clemmons DR, Moses AC, McKay MJ, et al. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. . Clin Endocrinol Metab 2000;85:1518-1524.
75. Crowne EC, Samra JS, Cheetham T, et al. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus. Metabolism 1998;47:31-38.
76. O'Connell T, Clemmons DR. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. . Clin Endocrinol Metab 2002;87:4356-4360.
77. Vestergaard H, Rossen M, Urhammer SA, et al. Short-and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus. Eur J Endocrinol 1997;136:475-482.
78. Usala AL, Madigan T, Burguera B, et al. Brief report: treatment of insulinresistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes. . Engl J Med 1992;327:853-857.
79. Zenobi, PD, Jaeggi-Groisman SE, Riesen WF, et al. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. . Clin Invest 1992;90:2234-2241.
80. Klinger B, Anin S, Silbergeld A, et al. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin Endocrinol (Oxf) 1998;48:81-87.
81. Duleba AJ, Spaczynski RZ, Olive DL. Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca-interstitial cells. Fertil Steril 1998;69:335-340.
82. Gdansky EY, Diamant Z, Laron Z, et al. Increased number of IGF-I receptors on erythrocytes of women with polycystic ovarian syndrome. Clin Endocrinol (Oxf) 1997;47:185-190.
83. Cataldo NA. Insulin-like growth factor binding proteins: do they play a role in polycystic ovary syndrome? Semin Reprod Endocrinol 1997;15:123-136.
84. Mason HD, Cwyfan-Hughes SC, Heinrich G, et al. Insulin-like growth factor (IGF) I and II, IGF-binding proteins, and IGF-binding protein proteases are produced by theca and stroma of normal and polycystic human ovaries. . Clin Endocrinol Metab 1996;81:276-284.
85. Voutilainen R, Franks S, Mason HD, et al. Expression of insulin-like growth factor (IGF), IGF-binding protein, and IGF receptor messenger ribonucleic acids in normal and polycystic ovaries. . Clin Endocrinol Metab 1996; 81:1003-1008.
86. Kohner EM, Hamilton AM, Joplin GF, et al. Florid diabetic retinopathy and its response to treatment by photocoagulation or pituitary ablation. Diabetes 1976;25:104-110.
87. Janssen JA, Jacobs ML, Derkx FH, et al. Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. . Clin Endocrinol Metab 1997;82: 2809-2815.
88. Dills DG, Moss SE, Klein R, et al. Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes1991; 40:1725-1730.
89. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997;276:1706-1709.
90. Kondo TD, Vicent D, Suzuma M, et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. . Clin Invest 2003;111:1835-1842.
91. Growth Hormone Antagonist for Proliferative Retinopathy Study Group. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001;108:2266-2272.
92. Cianfarani S, Bonfanti R, Bitti ML, et al. Growth and insulin-like growth factors (IGFs) in children with insulin-dependent diabetes mellitus at the onset of disease: evidence for normal growth, age dependency of the IGF system alterations, and presence of a small (approximately 18-kilodalton) IGF-binding protein-3 fragment in serum. . Clin Endocrinol Metab 2000;85:4162-4167.
93. Cummings EA, Sochett EB, Dekker MG, et al. Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes. Diabetes 47:1341-1346.
94. Bach LA. IGF-I and IGF binding proteins in diabetes-related kidney growth. Growth Regul 1992;2:30-39.
95. Flyvbjerg A. Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes. Kidney Int Suppl 1997;60:S12-9:S12-9.
96. Horney MJ, Shirley DW, Kurtz DT, et al. Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I. Am J Physiol 1998;274: F1045-F1053.
97. Gronbaek H, Nielsen B, Frystyk J, et al. Effect of lanreotide on local kidney IGF-I and renal growth in experimental diabetes in the rat. Exp Nephrol 1996;4:295-303.
98. Bellush LL, Doublier S, Holland AN, et al. Protection against diabetesinduced nephropathy in growth hormone receptor/binding protein genedisrupted mice. Endocrinology 2000;141:163-168.
99. Zhuang HX, Wuarin L, Fei ZJ, et al. Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with non-insulindependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy. . Pharmacol Exp Ther 1997;283:366-374.
100. Ishii DN. Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Rev 1995;20:47-67.
101. Russell JW, Feldman EL. Insulin-like growth factor-I prevents apoptosis in sympathetic neurons exposed to high glucose. Horm Metab Res 1999;31:90-96.
102. Cheng HL, Steinway M, Delaney CL, et al. IGF-I promotes Schwann cell motility and survival via activation of Akt. Mol Cell Endocrinol 2000;170: 211-215.